VISX sees US rivals set to mount licence challenge
This article was originally published in Clinica
VISX failed just before Christmas to protect three of its laser optical surgery patents in Canada, fuelling speculation that rivals such as Nidek, Bausch & Lomb and LaserSight may now be able to break the dominant position VISX claims in the US, the only country where it demands per-use licence fees of $250.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.